Please ensure Javascript is enabled for purposes of website accessibility

Why Spectrum Pharmaceuticals Stock Is Crashing Today

By Keith Speights – Aug 6, 2021 at 11:28AM

Key Points

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company received a thumbs-down from the FDA for its lead pipeline candidate.

What happened

Shares of Spectrum Pharmaceuticals (SPPI -0.51%) were crashing 26.3% lower as of 11:14 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Food and Drug Administration turned down approval of Rolontis in treating neutropenia in patients receiving cancer drugs that decrease bone marrow activity. 

So what

There's good news and bad news for Spectrum with the FDA's rejection of Rolontis. The bad news is obvious: Spectrum won't be able to market the drug as soon as it would like. The good news, though, is that it isn't the end of the road for Rolontis.

"FDA Not Approved" stamp.

Image source: Getty Images.

The FDA's complete response letter didn't raise issues about the safety or efficacy of Spectrum's drug. Instead, the agency mentioned manufacturing concerns that will require another inspection of the company's facility.

Now what

Spectrum stated in a press release that it plans to meet with the FDA as soon as possible to receive more clarification on the manufacturing issues. "We are disappointed with this outcome and look forward to fully understanding the remediation timelines for the program," CEO Joe Turgeon said in a statement. "We continue to believe in Rolontis and plan to diligently complete the regulatory process to bring Rolontis to market."

The biotech stock could have another positive catalyst in the meantime, though. Spectrum hopes to file for FDA approval later this year for poziotinib in treating non-small cell lung cancer. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Spectrum Pharmaceuticals Stock Quote
Spectrum Pharmaceuticals
$0.47 (-0.51%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.